Morris, S. E., Dziobek-Garrett, L., Strehlau, R., Schröter, J., Shiau, S., Anelone, A., Paximadis, M., de Boer, R. J., Abrams, E. J., Tiemessen, C. T., Kuhn, L., & Yates, A. J. (2020).
Journal of acquired immune deficiency syndromes (1999), 10.1097/QAI.0000000000002425. Advance online publication. https://doi.org/10.1097/QAI.0000000000002425
Background: Mathematical modeling has provided important insights into HIV infection dynamics in adults undergoing antiretroviral treatment (ART). However, much less is known about the corresponding dynamics in perinatally-infected neonates initiating early ART.
Setting: From 2014-2017, HIV viral load (VL) was monitored in 122 perinatally-infected infants identified at birth and initiating ART within a median of two days. Pre-treatment infant and maternal covariates, including CD4 T cell counts and percentages, were also measured.
Methods: From the initial cohort, 53 infants demonstrated consistent decline and suppressed VL below the detection threshold (20 copies ml) within one year. For 43 of these infants with sufficient VL data, we fit a mathematical model describing the loss of short and long-lived infected cells during ART. We then estimated the lifespans of infected cells and the time to viral suppression, and tested for correlations with pre-treatment covariates.
Results: The majority of parameters governing the kinetics of VL decline were consistent with those obtained previously from adults and other infants. However, our estimates of the lifespan of short-lived infected cells were longer than published values. This difference may reflect sparse sampling during the early stages of VL decline, when the loss of short-lived cells is most apparent. In addition, infants with higher pre-treatment CD4 percentage or lower pre-treatment VL trended towards more rapid viral suppression.
Conclusions: HIV dynamics in perinatally-infected neonates initiating early ART are broadly similar to those observed in other age groups. Accelerated viral suppression is also associated with higher CD4 percentage and lower VL.